Aerovate Therapeutics, Inc. financial data

Symbol
AVTE on Nasdaq
Location
930 Winter Street, Suite M 500, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 733 % -47.4%
Debt-to-equity 15.8 % +94.7%
Return On Equity -83.7 % -69.8%
Return On Assets -72.3 % -58.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28.9M shares +4.41%
Common Stock, Shares, Outstanding 28.9M shares +4.54%
Entity Public Float 232M USD +47.5%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 28.8M shares +14.3%
Weighted Average Number of Shares Outstanding, Diluted 28.8M shares +14.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 76M USD +44.7%
General and Administrative Expense 18.2M USD +17.7%
Operating Income (Loss) -94.2M USD -38.6%
Nonoperating Income (Expense) 1.81M USD +220%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.9M USD -292%
Net Income (Loss) Attributable to Parent -87.9M USD -37.1%
Earnings Per Share, Basic -3.13 USD/shares -20.8%
Earnings Per Share, Diluted -3.13 USD/shares -20.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.1M USD -49%
Cash, Cash Equivalents, and Short-term Investments 104M USD -30.6%
Assets, Current 111M USD -27.4%
Property, Plant and Equipment, Net 232K USD -5.31%
Operating Lease, Right-of-Use Asset 621K USD -23.4%
Other Assets, Noncurrent 81K USD -96.4%
Assets 112M USD -28.3%
Accounts Payable, Current 4.18M USD -24.4%
Employee-related Liabilities, Current 2.66M USD +74.6%
Liabilities, Current 17M USD +28.1%
Operating Lease, Liability, Noncurrent 206K USD -56.7%
Liabilities 17.3M USD +25.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -83K USD +62.8%
Retained Earnings (Accumulated Deficit) -211M USD -71.2%
Stockholders' Equity Attributable to Parent 94.4M USD -33.5%
Liabilities and Equity 112M USD -28.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.7M USD -107%
Net Cash Provided by (Used in) Financing Activities 471K USD +111%
Net Cash Provided by (Used in) Investing Activities 8.83M USD -42.6%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 28.9M shares +4.54%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.4M USD -444%
Deferred Tax Assets, Valuation Allowance 43.6M USD +87.2%
Deferred Tax Assets, Gross 43.8M USD +85.7%
Operating Lease, Liability 681K USD -20.4%
Depreciation 28K USD +33.3%
Payments to Acquire Property, Plant, and Equipment 16K USD -42.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -87.8M USD -38.1%
Lessee, Operating Lease, Liability, to be Paid 710K USD -22.1%
Operating Lease, Liability, Current 475K USD +25.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 242K USD -52.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 242K USD +49.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29K USD -49.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 242K USD -50.5%
Deferred Tax Assets, Operating Loss Carryforwards 16.2M USD +37.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.21M USD +123%
Lessee, Operating Lease, Liability, to be Paid, Year Four 242K USD
Operating Lease, Payments 127K USD +3.25%
Additional Paid in Capital 306M USD +15.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 206K USD -31.8%
Share-based Payment Arrangement, Expense 14.6M USD +68.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%